A study in humans identified the miR-6752-5p as a biomarker for recurrent myocardial infarction risk, where it was downregulated in whole blood of patients with recurrent MI after percutaneous coronary intervention, with this differential expression remaining significant after false-discovery rate correction, though it was not significantly different in plasma samples [Onuoha et al. DOI:10.1111/cts.13307]. In a separate investigation of patients with sepsis, the miR-6752-5p was identified as downregulated in the peripheral blood of affected individuals compared to healthy controls [Xu et al. DOI:10.3892/mmr.2022.12850].